Key result
Mitral valve repair shows similar 2-year recurrent MR rates compared to replacement in ischemic MR.
Why the study?
Recent reports suggested better hemodynamic performance with mitral valve replacement than repair without survival differences at 2 years, prompting further evaluation of outcomes including hemodynamics at 1 and 2 years.
Does mitral valve repair improve or prevent moderate to severe mitral regurgitation compared to mitral valve replacement in adults with ischemic mitral regurgitation requiring revascularization?
Cohort (n=111)
No
Does mitral valve repair improve or prevent moderate to severe mitral regurgitation compared to mitral valve replacement in adults with ischemic mitral regurgitation requiring revascularization?
In patients with ischemic mitral regurgitation requiring revascularization, mitral valve repair showed mid-term hemodynamic durability and survival comparable to mitral valve replacement, suggesting it remains a viable option in well-selected patients.
Answers are grounded in this paper and cite their sources.
Repair was associated with similar 2-year MR rates; leaves open optimal strategy pending randomized data in ischemic MR.
OBJECTIVE: Recent reports on ischemic mitral valve (MV) regurgitation surgical strategies have suggested better hemodynamic performance with MV replacement (MVR) than MV repair (MVr) with no survival difference at 2 years. We evaluated the difference between MVR and MVr outcomes in patients with ischemic MR, including hemodynamic MV performance at 1 and 2 years postoperatively. METHODS: A single center cardiac surgery database was queried for patients (aged >/ = 18 years) requiring mitral valve surgery with concomitant CABG or PCI between January 2010 and June 2018. Patients were separated into two groups: mitral valve repair using ring annuloplasty (MVr) and mitral valve replacement (MVR). RESULTS: A total of 111 patients (median age 66 years, 76% male) underwent an operation for ischemic mitral regurgitation during the study period. (44%) had MVr and 62 (56%) had MVR. Both groups had > 80% concomitant CABG. The MVr group had lower EF (40% vs. 55%, p < 0.01), shorter cardiopulmonary bypass time (117 vs. 164 minutes, p < .01) and shorter aortic cross-clamp time (80 vs. 116 minutes, p < .01). The in-hospital mortality (6% vs. 10%, p = 1.00) and 1-year mortality (14% vs. 18%, p = 0.17) were similar between the groups. Pre-operative left ventricular internal diameter at end-diastole was greater in the MVr group (5.6cm vs. 4.6cm, p < .01). At 1-year, more patients in the MVR group had no or trace regurgitation (29% vs. 61%, p = 0.01), however, the number of patients with moderate or greater mitral regurgitation was similar (6% vs. 12%, p = 0.69). At 2-years, the MVr and MVR groups had no difference in moderate or severe mitral regurgitation (7% vs. 13%, p = 0.68). CONCLUSION: Our findings demonstrate similar early mortality and mid-term mitral valve performance, suggesting that MV repair could be a good surgical option in patients with ischemic MR requiring surgical revascularization.
No takes yet. Share an insight, caveat, or question.
Sweeney et al. (2024) conducted a cohort in Ischemic mitral regurgitation (n=111). Mitral valve repair using ring annuloplasty vs. Mitral valve replacement was evaluated on Moderate or severe mitral regurgitation at 2 years (p=0.68). Mitral valve repair resulted in similar rates of moderate or severe mitral regurgitation at 2 years compared to mitral valve replacement in patients with ischemic mitral regurgitation.
Synapse has enriched 10 related papers. Consider them for comparative context: